Soligenix (SNGX) Return on Capital Employed (2011 - 2026)
Soligenix's (SNGX) quarterly Return on Capital Employed came in at 262.43% in Q1 2026, down 45.45% on a QoQ basis from 180.42% in Q4 2025.
Soligenix (SNGX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Soligenix (SNGX) has 16 years of Return on Capital Employed data on file, last reported at 262.43% in Q1 2026.
- Quarterly Return on Capital Employed changed N/A year-over-year to 262.43% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 262.43% (changed N/A YoY) and the FY2025 annual result came in at 219.29%, down 1107.0% from the prior year.
- Return on Capital Employed retreated to 262.43% in Q1 2026, from 180.42% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 3530.35% in Q4 2022 to a low of 928.19% in Q1 2023.
- A 5-year average of 20.52% and a median of 177.73% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 358989 bps — and 2023, when it slumped 370539 bps.
- Tracing SNGX's Return on Capital Employed over 5 years: stood at 3530.35% in 2022, then slumped by 105 bps to 175.03% in 2023, then fell by 11 bps to 193.7% in 2024, then advanced by 7 bps to 180.42% in 2025, then sank by 45 bps to 262.43% in 2026.
- The last three Return on Capital Employed figures came in at 262.43% (Q1 2026), 180.42% (Q4 2025), and 236.68% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | -219.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -219.07% |
| Mar 31, 2026 | -262.43% |
| Dec 31, 2025 | -180.42% |
| Sep 30, 2025 | -236.68% |
| Jun 30, 2025 | -363.86% |
| Dec 31, 2024 | -193.70% |
| Sep 30, 2024 | -139.43% |
| Jun 30, 2024 | -298.36% |
| Mar 31, 2024 | -446.39% |
| Dec 31, 2023 | -175.03% |
| Sep 30, 2023 | -129.63% |
| Jun 30, 2023 | -155.56% |
| Mar 31, 2023 | -928.19% |
| Dec 31, 2022 | 3,530.35% |
| Sep 30, 2022 | -152.36% |
| Jun 30, 2022 | -113.27% |
| Mar 31, 2022 | -83.43% |
| Dec 31, 2021 | -59.53% |
| Sep 30, 2021 | -56.59% |
| Jun 30, 2021 | -47.33% |